|
|
By Frank Bedu-Addo, Ph.D., and Gregory Conn, Ph.D., PDS Biotech
The ability to build up cancer-attacking T cells in cancer patients remains a major limitation of current immunotherapy approaches. PDS Biotech's CEO and CSO share four lessons they have learned along the way in developing their lead product, PDS0101, an immunotherapy targeting HPV-positive cancers.
|